Last reviewed · How we verify

NCT05437588

Neural-Derived Plasma Exosomal MicroRNAs As Promising Novel Biomarkers for Suicidality and Treatment Outcome in Adolescents

Recruiting now NA Last updated 11 July 2025
What this trial tests

NA trial testing Genetic testing in Major Depressive Disorder in 240 participants. Currently enrolling.

Timeline
1 October 2022
Primary endpoint
29 June 2027
30 June 2027

Quick facts

Lead sponsorUniversity of Alabama at Birmingham
PhaseNA
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposeprevention
Enrollment240
Start date1 October 2022
Primary completion29 June 2027
Estimated completion30 June 2027
Sites2 locations across United States

Drugs / interventions tested

Conditions studied

Sponsor

University of Alabama at Birmingham

Who can join

Adults 10 to 24, any sex, with Major Depressive Disorder or Suicidal Ideas. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is dedicated to help identify biomarkers for depression and suicide. The purpose of the study is to better understand these links to improve medical and psychiatric care in the future. This research is also to test the effects of standard treatment of depression on improvement in depressive and suicidal behavior and on biomarkers (e.g. miRNA) for these disorders.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Genetic testing

Trials testing the same drug.

Other recruiting trials for Major Depressive Disorder

Currently open trials in the same condition.

Other University of Alabama at Birmingham trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05437588.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing